Telo Genomics Corp. is a molecular diagnostics company, which engages in the development of telomere analysis platforms in the industry. The company is headquartered in Toronto, Ontario. The company went IPO on 2012-02-15. Its technologies utilize a multi-step process that involves capturing sample cells from blood or tissue, labeling, 3D formatting, processing and analyzing with TeloView. Its technologies are based on single cell biology. TeloView is a software platform, which is used to quantify specific features of each patient’s telomeres. The company quantifies six specific biological and structural features of telomeres and builds a score for each patient to assess their risk of disease progression and potential treatment response. TeloView helps in capturing the heterogeneity and complexity of cancers with relatively small sample sizes in clinical studies. Its initial lead includes multiple myeloma, prostate cancer and Alzheimer's disease.
TDSGF stock price ended at $0.03 on 月曜日, after dropping 25.00%
On the latest trading day Feb 02, 2026, the stock price of TDSGF fell by 25.00%, dropping from $0.04 to $0.03. During the session, the stock saw a volatility of 33.33%, with prices oscillating between a daily low of $0.03 and a high of $0.04. On the latest trading day, the trading volume for TDSGF rose by 1.4K shares, despite the declining prices. This uptick in volume may signal heightened risk in the near term. In total, 1.9K shares were traded, with a market value of approximately --.